ABSTRACT
L
urasidone is an atypical antipsychotic agent that acts as an antag onist with high affinity for the 5hydroxytryptamine (5HT) 2A , dopamine D 2 , and 5HT 7 receptors. 1 Lurasidone has shown efficacy in the treatment of acute exacerbation of schizophrenia in a series of shortterm, placebocontrolled studies. [2] [3] [4] [5] [6] Although treatment with some atypical antipsychotics has been associated with weight gain, elevated blood glucose, and dyslipidemia, [7] [8] [9] treatment with lurasidone has not been associated with significant disturbances in lipids or glycemic control and had minimal effect on weight, based on combined data from 5 shortterm (6week), placebocontrolled studies 6, 10 and data from a 12month activecontrolled study. 11 Similarly, 3 weeks to 12 months of treatment with lurasidone was not associated with clinically meaningful changes in the QTc interval. [2] [3] [4] 11 This 6month, openlabel extension study was preceded by a 6week, doubleblind study in which the shortterm safety and efficacy of once daily, fixed doses of lurasidone (40 mg or 120 mg) or olanzapine 15 mg for the treatment of schizophrenia were compared with placebo. 4 In the preceding doubleblind study, both doses of lurasidone and olanzapine demonstrated comparable efficacy versus placebo, based on change in Positive and Negative Syndrome Scale (PANSS) and Clinical Global ImpressionsSeverity of Illness (CGIS) scores. Lurasidone was generally well tolerated in this 6week trial, although it was associated with higher rates of akathisia, parkinsonism, and dystonia than was olanzapine. Because of the chronicity of schizophrenia and the need for prolonged therapy, it is important to assess the longterm effects of new antipsychotic medications. This 6month, openlabel extension study evaluated the safety and tolerability of oncedaily, flexibly dosed lurasidone (40-120 mg/d) for patients who completed the preceding doubleblind, placebocontrolled registration study. 4 Written informed consent was provided by all patients prior to enrollment into this study. The study protocol was approved by an Independent Ethics Committee associated with each study center. The study was conducted in accordance with Good Clinical Practice. 12 The study is registered with ClinicalTrials.gov (identifier: NCT00615433).
Assessments
The primary objective of this 6month, openlabel extension study was to assess the longterm safety and tolerability of lurasidone in patients with schizophrenia; in addition, the longerterm efficacy of lurasidone was evaluated.
Assessment visits occurred at baseline of the open label study, day 10 (following 3day placebo washout and 7 days of lurasidone 80 mg/d), and monthly thereafter for 6 months. Adverse events were recorded at each visit; assessment of medication tolerability was based, in part, on treatment discontinuation due to adverse events. Extrapyramidal symptoms (EPS) were assessed at each visit with the SimpsonAngus Scale, 13 Barnes Akathisia Rating Scale, 14 and Abnormal Involuntary Movement Scale. 15 Safety evaluation also included laboratory tests (chemistry and hematology panels, lipid panel, glycosylated hemoglobin [HbA 1c ], and prolactin), electrocardiograms (ECGs), and vital sign measurements. Efficacy was assessed using the PANSS total and subscale scores 16 and CGIS. 15 Treatment compliance was evaluated at each monthly visit using tablet counts. Patients were instructed to return with the blister packs dispensed at the previous study visit, and the remaining tablets of study medication were counted. Treatment compliance was calculated as (number of tablets missing)/(number of tablets prescribed) × 100. Patients were considered compliant if the number of doses missing was within 75%-125% of the prescribed doses. Mean estimated treatment compliance was the average of individual compliance values for patients with available compliance data across all visits. Such tablet counts, as obtained in clinical trials, may not fully reflect actual adherence to treatment.
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Statistical Methods
The primary analysis population comprised all patients who continued into the extension study and received at least 1 lurasidone dose (safety population). For each safety and efficacy measure, change scores were calculated from doubleblind baseline to openlabel study endpoint and from openlabel baseline to openlabel study endpoint (month 6). Additional prespecified analyses were conducted for 3 patient cohorts based on randomized treatment assignment in the preceding doubleblind study (to lurasidone, olanzapine, or placebo). For patients who did not complete the study, the last postbaseline observation was carried forward to openlabel study endpoint for the LOCF analyses as appropriate.
RESULTS
Patient Disposition and Study Treatment
Of the 298 patients who completed the preceding doubleblind study, 254 (85.2%) continued into the openlabel extension study. Patients entered the open label extension study from doubleblind treatment with lurasidone 40 mg/d or 120 mg/d (n = 118), olanzapine 15 mg/d (n = 71), or placebo (n = 65). Of the 254 patients, 113 (44.5%) completed the openlabel extension study ( Figure  1 ). The safety population (N = 246) excluded 8 patients who did not receive any dose of study medication after entering the extension study. The overall discontinuation rate for patients who had initially received placebo was 58.5%, compared with 56.3% for patients who had initially received olanzapine and 53.4% for patients who continued treatment with lurasidone. Adverse events resulted in early discontinuation for 12.6% of patients (14.4% of patients who had received lurasidone, 12.3% of patients who had received placebo, and 9.9% of patients who had received olanzapine). "Insufficient clinical response" was the reason for discontinuation for 6.7% of patients (7.6% of patients who had received lurasidone, 7.0% of patients who had received olanzapine, and 4.6% of patients who had received placebo).
Patient demographic and clinical characteristics at baseline are shown in Table 1 (safety population). The mean daily dose of lurasidone during the openlabel extension study was 86.3 mg; the modal dose was 80 mg/d for 63.0% of patients, 40 mg/d for 9.9% of patients, and 120 mg/d for 27.2% of patients. Median duration of lurasidone exposure during the openlabel extension study was 152.0 days; study completers received 193 days of openlabel treatment. The proportion of patients continuing at 6, 12, 16, and 24 weeks of the extension study was 72.0%, 58.8%, 53.1%, and 46.5%, respectively.
Information about treatment compliance was available for 197 patients (80.1%). Mean treatment compliance for these patients was 99.4%. Seventyfour percent of patients (n = 182) received concomitant medication(s). The most commonly used medications were anxiolytics (35% of patients), anticholinergics (32% of patients), and hypnotics and sedatives (26% of patients).
Clinical Points
Open-label treatment with flexibly dosed lurasidone ■ (40-120 mg/d) was effective and generally well tolerated over a 6-month period in patients who had completed 6 weeks of acute treatment with lurasidone, olanzapine, or placebo.
Patients who initially received placebo or lurasidone for 6 ■ weeks experienced a small increase in weight and minimal changes in metabolic parameters during subsequent treatment with open-label lurasidone for up to 6 months, whereas patients previously treated with olanzapine experienced weight loss and improvement in lipid levels after switching to lurasidone.
The most frequent adverse events associated with lurasidone ■ in this open-label extension study were akathisia and insomnia.
Safety
Adverse events. During this study, 162 patients (65.9%) reported at least 1 adverse event. The most commonly reported adverse events were akathisia (13.0%), insomnia (11.0%), nausea (9.8%), somnolence (9.8%), and parkinsonism (9.3%) ( Table 2 ). The majority of adverse events were classified as mild or moderate. Thirty of 246 patients in the safety population (12.2%) discontinued because of an adverse event. The most common adverse events resulting in discontinuation were psychiatric disorders (n = 16 [6.5%]) and nervous system disorders (n = 8 [3.3%]).
Twentyeight patients (11.4%) experienced serious adverse events (14.5% of patients who had received placebo, 10.4% of patients who had received lurasidone, and 10.1% of patients who had received olanzapine); no deaths occurred. Worsening of schizophrenia (n = 9 [3.7%]) and psychotic disorder or acute psychosis (n = 7 [2.8%]) were the 2 most common serious adverse events. In addition, there was 1 case (0.4%) of suicidal ideation and 1 (0.4%) suicide attempt.
In general, the frequency of adverse events appeared not to be related to treatment assignment during the preceding doubleblind study, with the exception of nausea, which was reported in 19.4% of patients who had received placebo during the doubleblind study and were started on lurasidone ( Table 2) . Half of these reports of nausea occurred during the first 3 weeks of treatment with lurasidone in the openlabel extension study. Body weight, body mass index, and waist circumference. For patients who continued into the openlabel extension phase, mean weight gain (observed cases [OC]) during the preceding 6week, doubleblind study, which included at least 3 weeks of inpatient hospitalization, was similar for patients receiving lurasidone (1.5 kg, n = 115) or placebo (1.6 kg, n = 62), but higher for patients receiving olanzapine (4.6 kg, n = 69) ( Figure 2 ). Patients who received lurasidone during both the doubleblind and openlabel studies experienced mean weight gain of 1.6 kg during 8 months of lurasidone exposure (OC, n = 56). For all patients in the openlabel extension study, there was a slight mean decrease in weight (−0.1 kg) from openlabel baseline to study endpoint (OC). During the openlabel extension study, mean weight (OC) was generally stable for patients continuing on lurasidone (+0.4 kg, n = 56) and increased slightly (+0.9 kg, n = 28) for patients who had received placebo during the preceding doubleblind study (Table 3 ; Figure 2 ). In contrast, patients who had received olanzapine during the preceding double blind study experienced a reduction in mean weight (−1.9 kg, n = 31) during openlabel treatment with lurasidone. A similar pattern of results was observed for body mass index. Overall, 8.7% of patients experienced ≥ 7% weight gain and 13.9% of patients experienced ≥ 7% weight loss during the openlabel extension study (OC ; Table 3 ); a ≥ 7% weight increase was most common in patients who had received placebo during the preceding doubleblind study (17.9%), and a ≥ 7% weight reduction was most common in patients who had received olanzapine (29.0%). Metabolic parameters. Lipids. For patients who continued into the openlabel extension phase, median changes in lipid levels during the preceding 6week, doubleblind study (OC) were generally small and similar for patients who received lurasidone (−3.0 mg/dL for total cholesterol, −3.0 mg/dL for lowdensity lipoprotein [LDL] cholesterol, 0.0 mg/dL for highdensity lipoprotein [HDL] cholesterol, +1.0 mg/dL for triglycerides) or placebo (−1.5 mg/dL for total cholesterol, 0.0 mg/dL for LDL cholesterol, −0.5 mg/dL for HDL cholesterol, +1.5 mg/dL for triglycerides), whereas patients who received olanzapine had increases in median total cholesterol (+15.0 mg/dL), LDL cholesterol (+7.0 mg/dL), and triglycerides (+27.0 mg/dL) and a decrease in median HDL cholesterol (−2.0 mg/dL) during the doubleblind study.
For patients who received lurasidone during both the doubleblind and openlabel studies, changes in median lipid levels after 8 months of lurasidone exposure (OC) were −12.0 mg/dL for total cholesterol, −2.0 mg/dL for LDL cholesterol, −2.0 mg/dL for HDL cholesterol, and +4.0 mg/dL for triglycerides. During openlabel treatment with lurasidone, patients who had received olanzapine in the doubleblind study experienced larger changes in median lipid levels (−15.0 mg/dL in total cholesterol, −4.0 mg/dL in LDL cholesterol, and −28.0 mg/dL in triglycerides; OC) compared with patients who had received lurasidone during the doubleblind study (−2.0 mg/dL for total cholesterol, 0.0 mg/dL for LDL cholesterol, and −5.0 mg/dL for triglycerides; OC) (Table 3) . Median HDL cholesterol increased (+2.0) in the olanzapinetolurasidone subgroup and decreased (−2.0 mg/dL) for patients continuing on lurasidone (OC). The placebotolurasidone subgroup showed a decrease in median total cholesterol (−5.0 mg/dL) and triglycerides (−8.0 mg/dL) during the openlabel extension study, a slight increase (+3.0 mg/dL) in LDL cholesterol, and no change in HDL cholesterol (OC).
For patients who had received placebo during the double blind study, a shift from normal values at openlabel baseline to high values at LOCF endpoint was observed in 9.8% of patients for total cholesterol (high defined as > 200 mg/dL), 7.8% of patients for LDL cholesterol (high defined as > 129 mg/dL), and 2.0% of patients for triglycerides (high defined as > 203 mg/dL); 5.9% of patients who had received placebo shifted from normal to low values of HDL cholesterol (low defined as < 35 mg/dL) in the openlabel study. For patients who had received olanzapine, shifts were noted in 6.9%, 5.2%, 8.6%, and 3.4% of patients for total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides, respectively; for patients continuing on lurasidone, shifts were experienced by 12.0%, 19.0%, 14.0%, and 8.0% of patients for the respective lipid parameters. Smaller shifts in lipid parameters for the cohort previously treated with olanzapine (compared with those previously treated with lurasidone) may have been due to the effects of olanzapine treatment on these parameters during the preceding 6week, doubleblind study.
Glucose, insulin, and glycosylated hemoglobin. For patients who continued into the openlabel extension phase, median changes in glucose, insulin, and HbA 1c levels during the preceding doubleblind study were small in every treatment group (OC). Median changes during the openlabel extension study were similarly small (Table 3) ; the proportion of patients who experienced a shift from normal value to high value (LOCF) was 16.8% for glucose (high defined as > 99 mg/dL), 7.0% for insulin (high defined as > 28.0 mU/L), and 1.9% for HbA 1c (high defined as > 6.0%).
Extrapyramidal symptoms. The proportion of patients who reported any EPSrelated treatmentemergent adverse event, including akathisia, during the extension study was 26.4%. The most commonly reported EPSrelated adverse events were akathisia (13.0%) and parkinsonism (9.3%) ( Table  2 ). There was a low incidence of other EPSrelated symptoms such as tremor (2.4%), restlessness (3.3%), and dystonia (3.7%). The incidence of any EPSrelated adverse event was similar irrespective of doubleblind treatment assignment. Five patients (2.0%) discontinued the study because of an EPSrelated adverse event: 3 patients for akathisia (2 who had received olanzapine and 1 who had received lurasidone in the preceding doubleblind study), 1 patient (who had initially received lurasidone) for dystonia (torticollis), and 1 patient (who had initially received lurasidone) for tremor. Mean change from openlabel baseline to study endpoint (LOCF) was 0.0 on the SimpsonAngus Scale mean score, 0.1 on the Barnes Akathisia Rating Scale global clinical assessment of akathisia, and 0.0 on the Abnormal Involuntary Movement Scale total score.
Prolactin. For patients who continued into the openlabel extension phase, median change in prolactin level during the preceding doubleblind study was +0.7 ng/mL for patients receiving lurasidone, −0.75 ng/mL for patients receiving placebo, and +3.9 ng/mL for patients receiving olanzapine (OC). For the overall patient population, there was a small decrease in median prolactin level from openlabel baseline to study endpoint (−1.3 ng/mL, OC); the median change was −1.3 ng/mL for patients who continued on lurasidone, −4.2 ng/mL for patients who had been treated with olanzapine, and 0.0 ng/mL for patients who had received placebo. A change from normal prolactin levels at openlabel baseline to high prolactin levels at LOCF endpoint occurred in 21 male patients (12.1%; criterion for high value > 17.7 ng/mL) and 6 female patients (10.9%; criterion for high value > 29.2 ng/mL).
Electrocardiographic parameters. There were no clinically meaningful changes in mean ECG parameters during the openlabel period. No patients had a QTcF interval of > 500 msec. One patient (0.4%) had a ≥ 60msec increase in QTcF interval from openlabel baseline at the month 6 assessment.
Physical examination and vital signs. There were no clinically meaningful changes in physical examination measures or vital signs (heart rate, systolic and diastolic blood pressure, body temperature) during openlabel treatment with lurasidone.
Efficacy
Patients who continued into the openlabel extension phase had shown substantial improvement in PANSS total score during the preceding doubleblind study (−33.0 points for patients receiving lurasidone, −31.6 for patients receiving olanzapine, and −23.1 for patients receiving placebo). In the openlabel extension study, patients demonstrated continued improvement in PANSS total score: overall mean change of -8.7 from openlabel baseline to month 6 (OC). Mean changes in PANSS total score during the extension study were −12.0 for the placebotolurasidone subgroup, −8.6 for patients who continued on lurasidone, and −5.8 for patients switched from olanzapine to lurasidone. A similar pattern of change was observed for the PANSS positive, negative, and general psychopathology subscales and the CGIS.
DISCUSSION
This openlabel extension study followed a 6week, doubleblind, placebocontrolled study of lurasidone at fixed daily doses of 40 mg or 120 mg, or olanzapine 15 mg/d. 4 During the doubleblind study, treatment with lurasidone and treatment with olanzapine both produced significant improvement in symptoms in patients experiencing an acute exacerbation of schizophrenia. 4 Post hoc analyses showed no significant differences between lurasidone and olanzapine on improvement in PANSS total or CGIS scores. 4 In this 6month extension study, openlabel treatment with lurasidone, flexibly dosed between 40 mg/d and 120 mg/d, was associated with sustained improvement in symptoms of schizophrenia, with further improvement noted in PANSS total and CGIS scores at study endpoint compared with openlabel baseline. Symptom control was maintained irrespective of treatment group assignment in the preceding doubleblind study; as expected, the greatest numeric improvement from openlabel baseline in PANSS total score was seen for patients initially treated with placebo in the acute study phase. The modal 80mg/d dose of lurasidone, used by almost twothirds of patients in this extension study, is consistent with that found in previous lurasidone flexible dose studies, 11, 18 suggesting this may be an optimal dose for many outpatients with schizophrenia.
The safety and tolerability profile of lurasidone in this extension study was consistent with findings from previously reported short and longerterm lurasidone studies in patients with schizophrenia. 2, 4, 10, 11, 19 Notably, openlabel treatment with lurasidone over 6 months in this study did not produce further weight gain beyond that observed during the initial 6 weeks of lurasidone treatment in the preceding acute study and was associated with improvement in lipid parameters, with no adverse changes in measures of glycemic control.
The incidence of parkinsonism (9.3%) and akathisia (13.0%) was also consistent with previous studies. In the preceding 6week, doubleblind study (which included olan zapine as an active control), a greater incidence of akathisia, parkinsonism, and dystonia was observed with lurasidone than with olanzapine. 4 However, evening administration of lurasidone in a recent 6week study 20 was associated with lower rates of akathisia (7.4%-8.0%), parkinsonism (5.6%-6.6%), and dystonia (1.7%-2.4%) than were observed in other clinical trials in which lurasidone was dosed in the morning. 6 It is possible that evening dosing may be better for lurasidone than the morning dosing employed in this study. In general, based on this and other studies, the incidence of akathisia with lurasidone appears comparable to that of other atypical antipsychotic agents, with the exception of somewhat higher rates than observed with olanzapine or quetiapine. 2, 4, 18, 21 This openlabel extension study was not intended as a formal switch study. However, because the preceding doubleblind study included olanzapine, the study design permitted assessment of the effects of switching from treatment with olanzapine to lurasidone (implemented after a brief washout and without crosstaper). Switch studies in patients with schizophrenia generally include patients who have experienced suboptimal efficacy or safety/tolerability with their current antipsychotic treatment. 22 In contrast, all patients who had completed doubleblind treatment with olanzapine were eligible to participate in this extension study, independent of their acute phase treatment outcome. In this context, it is notable that patients treated with lurasidone after conversion from olanzapine showed sustained improvement in efficacy, with a decrease in weight and lipid parameters to levels comparable to those of patients who were not initially treated with olanzapine. The magnitude of the reduction in weight and lipid parameters found after switching from olanzapine to lurasidone in this extension study appeared clinically relevant and suggests that lurasidone may be a useful treatment for patients with antipsychoticinduced weight gain or dyslipidemia. These improvements in metabolic parameters were consistent with those reported in other studies that have examined the effects of switching from atypical antipsychotic medications with higher metabolic liability to those with lower metabolic liability, [23] [24] [25] [26] [27] [28] as well as a recent metaanalysis of short and longerterm placebocontrolled and headto head trials of several atypical antipsychotics in patients with schizophrenia and bipolar disorder, which reported that lurasidone had the lowest potential for weight gain among the atypical antipsychotics studied. 29 Improvements in psychopathology and reductions in weight and dyslipidemia were also observed in a recently completed formal switch study in which stable outpatients with schizophrenia were switched to lurasidone from other antipsychotic agents. 18 However, switching from olanzapine to lurasidone in our extension study resulted in a modest increase in the incidence of akathisia, consistent with data reported from the formal lurasidone switch study. 18 Overall study discontinuation rates were comparable between patients switching from olanzapine and those continuing on lurasidone in this extension study. A com parable proportion of patients who switched from olanzapine or continued on lurasidone discontinued openlabel study participation because of insufficient clinical response. The rate of discontinuation because of an adverse event was slightly lower for patients switched from olanzapine compared with patients continued on lurasidone. There was an increased incidence of insomnia in patients who switched from olanzapine, but no increased incidence of anxiety, agitation, or other activationlike events that may be associated with a switch to a less sedating agent.
All firstgeneration antipsychotic agents and some second generation agents (notably, amisulpride and risperidone) have the potential to increase serum prolactin levels, which can lead to hyperprolactinemiaassociated complications such as infertility and sexual dysfunction. [30] [31] [32] After a modest increase during the preceding 6week doubleblind study in patients treated with either lurasidone or olanzapine, prolactin levels decreased during this 6month openlabel extension study, and median values at study endpoint were similar to those observed at doubleblind baseline.
Less than half of the patients (44.5%) who entered the openlabel extension completed the study; discontinuation was attributed to insufficient clinical response for 6.7% of patients. A similar discontinuation rate (53.2%) was shown in a pooled analysis of atypical antipsychotic studies with comparable duration of treatment (24-28 weeks). 33 Much greater 26week discontinuation rates (78%-83%) were observed in a health care claims database analysis of atypical antipsychotic medication use. 34 Limitations of this extension study include the open label design (which may bias in favor of the investigational treatment) and the lack of an active control arm (eg, patients who continued on olanzapine). In addition, although any openlabel extension study has potential for selection bias, 254 of the 298 patients (85.2%) who completed the preceding doubleblind study elected to continue in the openlabel extension. The demographic characteristics of patients at the acute phase baseline 4 were comparable with those reported at extension baseline, limiting the potential for a nonrepresentative patient sample in the current study.
The results of this openlabel, flexibledose, 6month extension study indicate that lurasidone in flexible doses ranging from 40 mg/d to 120 mg/d was generally safe and well tolerated and associated with sustained efficacy in the longerterm treatment of patients with schizophrenia. Lurasidone showed a low propensity for weight gain and minimal effects on metabolic parameters or prolactin and was associated with modest rates of EPS. These findings support the clinical utility of longerterm treatment with lurasidone in patients with schizophrenia.
